CN113646327A - 用于治疗肝脏疾病的ghrh或其类似物 - Google Patents

用于治疗肝脏疾病的ghrh或其类似物 Download PDF

Info

Publication number
CN113646327A
CN113646327A CN202080025127.2A CN202080025127A CN113646327A CN 113646327 A CN113646327 A CN 113646327A CN 202080025127 A CN202080025127 A CN 202080025127A CN 113646327 A CN113646327 A CN 113646327A
Authority
CN
China
Prior art keywords
ghrh
pharmaceutically acceptable
hexenoyl
trans
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080025127.2A
Other languages
English (en)
Chinese (zh)
Inventor
S·K·格林斯彭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of CN113646327A publication Critical patent/CN113646327A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080025127.2A 2019-03-29 2020-03-27 用于治疗肝脏疾病的ghrh或其类似物 Pending CN113646327A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962826284P 2019-03-29 2019-03-29
US62/826,284 2019-03-29
US201962861187P 2019-06-13 2019-06-13
US62/861,187 2019-06-13
PCT/US2020/025180 WO2020205498A1 (en) 2019-03-29 2020-03-27 Ghrh or analogues thereof for use in treatment of hepatic disease

Publications (1)

Publication Number Publication Date
CN113646327A true CN113646327A (zh) 2021-11-12

Family

ID=72607731

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080025127.2A Pending CN113646327A (zh) 2019-03-29 2020-03-27 用于治疗肝脏疾病的ghrh或其类似物

Country Status (10)

Country Link
US (4) US10799562B1 (https=)
EP (1) EP3947426A4 (https=)
JP (1) JP2022527190A (https=)
KR (1) KR20210145226A (https=)
CN (1) CN113646327A (https=)
AU (1) AU2020253828A1 (https=)
CA (1) CA3133319A1 (https=)
IL (1) IL286703A (https=)
SG (1) SG11202110469PA (https=)
WO (1) WO2020205498A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115884783A (zh) * 2020-07-05 2023-03-31 瑟瑞技术公司 Ghrh类似物的低剂量药物组合物及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202110469PA (en) 2019-03-29 2021-10-28 Massachusetts Gen Hospital Ghrh or analogues thereof for use in treatment of hepatic disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170296628A1 (en) * 2016-04-19 2017-10-19 Griffon Pharmaceuticals Inc. Pegylated bioactive peptides and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678083A (zh) * 2007-04-04 2010-03-24 瑟瑞技术公司 Ghrh分子的药物制剂
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US20150174207A1 (en) * 2013-12-24 2015-06-25 University Of Miami Methods for treating cancer with ghrh agonists
US20170105996A1 (en) * 2015-10-16 2017-04-20 Teva Pharmaceutical Industries, Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
KR20200121308A (ko) * 2018-02-14 2020-10-23 루모스 파마, 인크. 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물
SG11202110469PA (en) * 2019-03-29 2021-10-28 Massachusetts Gen Hospital Ghrh or analogues thereof for use in treatment of hepatic disease
WO2022093757A1 (en) * 2020-10-30 2022-05-05 The General Hospital Corporation Kits, reagents and methods for the assessment of liver diseases
US20220152012A1 (en) * 2020-11-16 2022-05-19 The Regents Of The University Of California Methods for regressing or reversing fibrosis and/or liver cirrhosis in a subject in need thereof using high-dose niacin, or a niacin analog thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170296628A1 (en) * 2016-04-19 2017-10-19 Griffon Pharmaceuticals Inc. Pegylated bioactive peptides and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LAURIE R. BRAUN等: "Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation", GROWTH HORMONE & IGF RESEARCH, vol. 37, pages 1 - 6, XP055887229, DOI: 10.1016/j.ghir.2017.10.002 *
STEVEN K. GRINSPOON: "Tesamorelin Effects on Liver Fat and Histology in HIV", pages 5 - 6, Retrieved from the Internet <URL:https://clinicaltrials.gov/study/NCT02196831?term=NCT02196831&rank=1&tab=history&a=12> *
TAKARA L. STANLEY等: "Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation A Randomized Clinical Trial", JAMA., vol. 312, no. 4, pages 380 - 389, XP055746137, DOI: 10.1001/jama.2014.8334 *
吕世华等: "替莫瑞林醋酸盐(tesamorelin)", 中国药物化学杂志, vol. 21, no. 3, pages 249 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115884783A (zh) * 2020-07-05 2023-03-31 瑟瑞技术公司 Ghrh类似物的低剂量药物组合物及其用途

Also Published As

Publication number Publication date
US10946073B2 (en) 2021-03-16
US11738066B2 (en) 2023-08-29
US10799562B1 (en) 2020-10-13
EP3947426A4 (en) 2023-01-04
WO2020205498A1 (en) 2020-10-08
EP3947426A1 (en) 2022-02-09
JP2022527190A (ja) 2022-05-31
US20240091316A1 (en) 2024-03-21
KR20210145226A (ko) 2021-12-01
US20200405816A1 (en) 2020-12-31
AU2020253828A1 (en) 2021-10-28
US12233107B2 (en) 2025-02-25
SG11202110469PA (en) 2021-10-28
IL286703A (en) 2021-10-31
US20210177943A1 (en) 2021-06-17
US20200306345A1 (en) 2020-10-01
CA3133319A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
JP6877472B2 (ja) Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法
EP2822591B1 (en) Pharmaceutical formulations of tnf-alpha antibodies
EP2403520B1 (en) Insulin formulations for rapid uptake
US20240325371A1 (en) Use of ezh2 inhibitor in preparation of drug for treating t-cell lymphoma
US12233107B2 (en) GHRH or analogues thereof for use in treatment of hepatic disease
EP2209528A1 (en) Rapid acting injectable insulin compositions
TWI893108B (zh) 司馬魯肽在醫學上的用途
WO2018171557A1 (zh) 一种长效化突变的人源成纤维生长因子的新用途
KR20200101960A (ko) 암치료약
EP3996680A1 (en) Stable formulations of recombinant proteins
CN115551510A (zh) 用于治疗由冠状病毒引起的肺炎和/或心肌炎的azd1656
CN115768461A (zh) 使用c1酯酶抑制剂治疗病毒感染相关的急性呼吸窘迫
WO2025096262A1 (en) Mdm2 degraders and uses thereof
TW202034955A (zh) 使用免疫調節治療癌症之新穎方法
CN118742305A (zh) 用于治疗疾病的口服奥曲肽
US20210113478A1 (en) Stabilized Composition
CN114761015A (zh) 中性粒细胞弹性蛋白酶抑制剂在肺病中的用途
EP3703733A1 (en) Methods and compositions for reducing lung injury associated with lung transplantation
WO2019122911A1 (en) Tranilast for cystic fibrosis
WO2026026911A1 (zh) 一种二肽衍生物的应用
CN120078888A (zh) 一种治疗肺癌的药物组合物及其应用
US20130079416A1 (en) Homeopathic medicament comprising phenacetin for the treatment of cancer
HK40073572B (zh) 酒精性肝炎的治疗
CN115884783A (zh) Ghrh类似物的低剂量药物组合物及其用途
NZ751555B2 (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211112

WD01 Invention patent application deemed withdrawn after publication